Left Ventricular Assist Device as a Bridge to Recovery: Single Center Experience of Successful Device Explantation

Robert S. Zhang, Thomas C. Hanff, Carli J. Peters, Peter T. Evans, Judy Marble, J. Eduardo Rame, Pavan Atluri, Kimberly Urgo, Monique S. Tanna, Jeremy A. Mazurek, Michael A. Acker, Marisa Cevasco, Edo Y. Birati, Joyce W. Wald

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Continuous-flow left ventricular assist devices (CF-LVAD) have been shown to enhance reverse remodeling and myocardial recovery in certain patients allowing for device removal. We sought to analyze the characteristics and describe outcomes of patients who underwent CF-LVAD explantation at a large academic center. We retrospectively identified all patients who underwent CF-LVAD explants due to recovery from 2006 to 2019. Patient baseline characteristics and data on pre- and postexplant evaluation were collected and analyzed. Of 421 patients who underwent CF-LVAD implantation, 13 underwent explantation (3.1%). Twelve HeartMate II and one HeartWare LVAD were explanted. All patients had nonischemic cardiomyopathy. Median time from heart failure diagnosis to LVAD implant was 12 months (interquartile range [IQR], 2-44) and the median time supported on LVAD was 22 months (IQR, 11-28). Two patients died within 30 days of explant. Three additional patients died during the follow-up period and all were noted to be nonadherent to medical therapy. After a mean follow-up duration of 5 years, overall survival was 52%. Mean pre-explant ejection fraction was 49%, which decreased at most recent follow-up to 32%. Mean pre-explant left ventricular internal diameter in diastole (LVIDD) was 4.37 cm and increased to 5.52 cm at most recent follow-up. Continuous-flow left ventricular assist device explantation is feasible and safe in select patients.

Original languageEnglish
Pages (from-to)822-828
Number of pages7
JournalASAIO Journal
Issue number6
StatePublished - 1 Jun 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.


Disclosures: Edo Y. Birati received consulting fees from American Regent Inc. Dr. Thomas C. Hanff was supported by the National Institute of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) T32 Training Grant HL-007891.

FundersFunder number
National Institutes of Health
National Heart, Lung, and Blood InstituteT32HL007891


    • LVAD
    • explant


    Dive into the research topics of 'Left Ventricular Assist Device as a Bridge to Recovery: Single Center Experience of Successful Device Explantation'. Together they form a unique fingerprint.

    Cite this